Mirion Technologies, Inc.

Mirion Technologies, Inc. (MIR) Market Cap

Mirion Technologies, Inc. has a market capitalization of $3.66B.

Price: $14.98

0.14 (0.94%)

Market Cap: 3.66B

NYSE · time unavailable

CEO: Thomas D. Logan

Sector: Industrials

Industry: Industrial - Machinery

IPO Date: 2020-08-20

Website: https://www.mirion.com

Mirion Technologies, Inc. (MIR) - Company Information

Market Cap: 3.66B|Sector: Industrials

Company Profile

Mirion Technologies, Inc., established in 2005 and formerly known as Global Monitoring Systems, Inc. until its name change in January 2006, is based in Atlanta, Georgia. The company specializes in providing a comprehensive suite of specialized solutions for radiation detection, measurement, analysis, and monitoring. Its operations span a wide international footprint, covering countries such as the United States, Canada, the United Kingdom, France, Germany, Finland, China, Belgium, the Netherlands, Estonia, and Japan. The business is organized into two distinct operating segments: Medical and Industrial. The Medical segment delivers critical solutions aimed at enhancing patient safety and treatment accuracy within healthcare environments. Offerings here include quality assurance and dosimetry tools for radiation oncology, specialized patient safety systems for diagnostic imaging and radiation therapy centers, and precision calibration and verification solutions for medical imaging and treatment accuracy. Furthermore, it supplies radionuclide therapy products, which encompass shielding, handling equipment, dedicated medical imaging furniture, and rehabilitation aids for nuclear medicine applications. This segment fundamentally supports advancements in medical diagnostics, cancer treatment, professional safety for practitioners, and patient recovery. Conversely, the Industrial segment addresses vital requirements in radiation safety, measurement, and analysis across non-medical industries. It furnishes clients with personal radiation detection devices, identification equipment, and advanced analytical instrumentation. Mirion's extensive product and solution portfolio includes a variety of items such as nuclear medicine preparations, personal dosimeters, contamination and clearance monitoring systems, and sophisticated reactor instrumentation and control equipment. They also provide both medical and industrial imaging systems along with their related accessories, in addition to specialized instruments for alpha spectroscopy, alpha/beta counting, and gamma spectroscopy detector systems. Supplementary offerings include electrical penetration components, cancer diagnostic tools, software solutions, and a range of other services. Mirion serves a broad and varied clientele across numerous sectors. This includes healthcare providers like hospitals, clinics, urgent care facilities, dental and veterinary offices, and specialized radiation treatment centers, as well as original equipment manufacturers (OEMs) for radiation therapy. Beyond healthcare, their customers extend to research laboratories, military organizations, governmental agencies, various industrial enterprises, power and utility companies, reactor design firms, and nuclear power plants (NPPs).

Analyst Sentiment

92%
Strong Buy

From 10 Active Polls

1Y Forecast: $25.80

▲ +72.2% Potential Upside

Consensus Target Metrics

Low Bound

$23

Median

$25

High Bound

$29

Average

$26

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$25.80
▲ +72.23% Upside
Low Target
$23.00
54% Risk
Median Target
$25.00
67% Mid
High Target
$29.00
94% Max
Consensus
Buy
8 / 9 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Period EndingTrailing 12MJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024
Market Cap ($M)3,6654,3864,5485,7245,2244,8523,2723,5772,288
Enterprise Value ($M)4,4795,2005,3846,5465,5235,4543,8064,1222,875
Price to Earnings Ratio (P/E)151.31149.42-334.3583.64450.78145.872788.4659.60-42.06
Price/Earnings-to-Growth Ratio (PEG)41.843.445023.8914.102.59
Price to Sales Ratio (P/S)3.5816.4417.6620.6423.4121.7716.2014.0711.06
Price to Book Ratio (P/B)2.012.402.473.072.843.322.182.381.51
Price to Free Cash Flow Ratio (P/FCF)26.7991.18483.8686.34401.834851.55120.7472.85586.64
Enterprise Value to Sales (EV/Sales)19.4920.9023.6024.7624.4718.8416.2113.90
Enterprise Value to EBITDA (EV/EBITDA)20.9991.72122.3796.55123.01123.6781.3264.5074.10
Debt to Equity Ratio3.820.680.670.660.670.590.480.480.47

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 MIRION TECHNOLOGIES INC CLASS A (MIR) — Investment Overview

🧩 Business Model Overview

Mirion Technologies supplies radiation detection and measurement solutions used to monitor, verify, and manage exposure risk across nuclear power, defense & homeland security, industrial radiological applications, and healthcare/medical workflows. The value chain spans (1) engineering and manufacturing of detectors and measurement systems, (2) integration into customer environments and workflows, and (3) lifecycle support such as calibration, servicing, dosimetry management, and compliance-related measurement services.

A key feature of the model is that once measurement equipment is qualified and integrated, customers rely on Mirion’s instruments and services to maintain regulatory compliance and operational safety—creating structural customer stickiness.

💰 Revenue Streams & Monetisation Model

Mirion monetizes through a blend of product and service revenue. Revenue is typically driven by:

  • System and equipment sales (detectors, monitoring systems, and measurement hardware) tied to nuclear, security, and industrial project activity.
  • Recurring or repeatable services including calibration, servicing, and related lifecycle support for in-place installations.
  • Dosimetry and measurement services where customers outsource exposure monitoring and data management, supporting ongoing compliance needs rather than one-time purchases.

Margin structure generally reflects that lifecycle services and measurement-related offerings tend to be more repeatable than new system installs, while the company’s measurement hardware benefits from scale in component sourcing and manufacturing know-how. Over time, the mix shift toward service and dosimetry-like recurring activities can support more stable gross margin and cash conversion than purely transactional equipment sales.

🧠 Competitive Advantages & Market Positioning

Mirion’s durable advantages center on high switching costs and regulatory/qualification barriers rather than consumer-style brand strength.

  • Switching Costs (Installed Base & Qualification): Radiation measurement is safety-critical. Customers often require specific performance specifications, calibration regimes, and validation within regulated environments. Re-qualifying alternate systems can be costly in both time and compliance risk, which increases customer retention.
  • Intangible Assets (Measurement Expertise & Technology): Proprietary detector technologies, signal processing, and engineering processes build cumulative know-how. Competitors can offer substitutable hardware, but matching performance and integration outcomes across customer sites is non-trivial.
  • Regulatory Moats (Compliance-Critical Workflows): Demand is anchored in meeting regulatory obligations (radiation safety, monitoring, and verification). This tends to favor vendors with proven track records, documentation, and service capability.

Competitive benchmarking:

  • Teledyne Technologies (radiation detection and related instrumentation offerings) competes for measurement solutions across government and industrial end markets.
  • Smiths Detection focuses heavily on detection and inspection equipment for security and checkpoint applications.
  • Thermo Fisher Scientific competes across elements of radiation measurement, dosimetry, and scientific/medical adjacencies depending on application.

Positioning contrast: Mirion’s emphasis spans civilian nuclear operations (including decommissioning and environmental monitoring), security/home-land applications, industrial radiological measurement, and dosimetry-related services, whereas some rivals skew more toward security-centric detection platforms (e.g., checkpoint/inspection) or broader scientific instrument portfolios. Mirion’s differentiation is the combination of measurement systems with ongoing lifecycle support and compliance workflows, which can be harder to replicate end-to-end.

🚀 Multi-Year Growth Drivers

A durable outlook rests on secular demand for radiation safety and verification. Over a 5–10 year horizon, addressable demand is supported by:

  • Nuclear lifecycle intensity: Extended operation of existing nuclear fleets, plus decommissioning and waste management, drives continuous needs for monitoring, verification, and radiation safety instrumentation.
  • Regulatory and compliance requirements: Governments and regulators require robust radiation monitoring and exposure tracking, favoring vendors that can provide measurement performance and sustained support.
  • Security and threat-detection modernization: Continued procurement and upgrades for radiation detection systems and improved sensing capabilities sustain program-based demand.
  • Industrial adoption in radiological processes: Growth in inspection and radiological applications expands the need for reliable measurement systems and safety oversight.
  • Healthcare/medical workflow demand: Where applicable, increased utilization of radiation-based therapies and diagnostics supports demand for measurement and quality assurance solutions that improve safety and workflow reliability.

Collectively, these trends support both (1) project-driven instrument demand and (2) ongoing service revenue anchored to an installed base—an important mix for multi-year earnings resilience.

⚠ Risk Factors to Monitor

  • Government and program budgeting risk: Security and defense-related demand can be influenced by procurement cycles and changes in government priorities.
  • Customer qualification and integration lead-time: Safety-critical systems can require long validation cycles; procurement delays can affect timing of revenue recognition.
  • Technology and performance risk: Competitors may introduce incremental improvements in detectors or analytics. Mirion must maintain performance credibility across regulated use cases.
  • Capital intensity and working-capital swings: Large system builds and project execution can create inventory and receivables volatility, impacting cash flow.
  • Concentration and end-market exposure: A portion of demand may track nuclear build/decommission schedules and regulated compliance budgets, which can vary by region and policy.
  • Regulatory and liability considerations: Radiation measurement is safety-critical; changes in standards, warranty/service obligations, or incident-related scrutiny can affect costs.

📊 Valuation & Market View

Markets typically value Mirion as an industrial technology and measurement/services business using a combination of:

  • EV/EBITDA and EV/Revenue to capture cyclicality versus service-like stability.
  • Forward margin and cash-flow expectations given the importance of mix (systems versus services/dosimetry-like recurring work) and operational execution.

Key valuation drivers include: sustainable service revenue contribution, evidence of durable customer retention tied to qualification and installed base, execution against project schedules, and cash conversion quality (working-capital management and lifecycle services scalability).

🔍 Investment Takeaway

Mirion’s investment case rests on measurement criticality and compliance-driven switching costs. The company is positioned to benefit from long-duration demand in nuclear lifecycle activities, radiation safety and monitoring requirements, and security modernization. The moat is less about a single product advantage and more about sustaining trust and performance across qualified installations through technology depth, lifecycle support, and regulatory fit.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for MIR.

marketbeat.com2026-07-30

Mirion Technologies Q2 Earnings Call Highlights

Mirion Technologies NYSE: MIR reported second-quarter revenue growth of nearly 20%, driven largely by acquisitions, while organic growth remained modest and the company maintained its full-year outlook on expectations for a stronger second half.

seekingalpha.com2026-07-29

Mirion Technologies, Inc. (MIR) Q2 2026 Earnings Call Transcript

Mirion Technologies, Inc. (MIR) Q2 2026 Earnings Call Transcript

zacks.com2026-07-28

Here's What Key Metrics Tell Us About Mirion Technologies (MIR) Q2 Earnings

Although the revenue and EPS for Mirion Technologies (MIR) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

zacks.com2026-07-28

Mirion Technologies, Inc. (MIR) Q2 Earnings Beat Estimates

Mirion Technologies, Inc. (MIR) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of $0.1 per share. This compares to earnings of $0.11 per share a year ago.

businesswire.com2026-07-28

Mirion Announces Second Quarter 2026 Financial Results

ATLANTA--(BUSINESS WIRE)--Mirion (“we” or the “company”) (NYSE: MIR), a global provider of radiation detection, measurement, analysis, and monitoring solutions to the nuclear, medical, defense, and research end markets, today announced results for the second quarter ended June 30, 2026. “Our second quarter performance reflects margin expansion across both operating segments, increased adjusted free cash flow, and continued orders and backlog growth,” commented Mirion's Chairman and Chief Execut.

zacks.com2026-07-27

Is the Options Market Predicting a Spike in Mirion Technologies Stock?

Investors need to pay close attention to MIR stock based on the movements in the options market lately.

zacks.com2026-07-21

Earnings Preview: Mirion Technologies, Inc. (MIR) Q2 Earnings Expected to Decline

Mirion Technologies (MIR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

etftrends.com2026-07-20

The Consortium Fueling the Nuclear Renaissance

The U.S. Department of Energy (DOE) published the approved voluntary agreement that formally establishes the Nuclear Fuel Cycle Consortium under the Defense Production Act (DPA). While the name centers on fuel production, the framework and its broad list of participants reach across the entire nuclear value chain.

etftrends.com2026-07-06

Microreactors Reach Milestones and Retailers Go Nuclear

The U.S. nuclear sector advanced on two fronts in recent days. Advanced microreactors completed a key federal target while the existing commercial fleet signed a landmark agreement with a major retailer.

etftrends.com2026-06-29

DOE's $17.5B Loan Boosts Nuclear Supply Chain

The U.S. Department of Energy announced a conditional commitment of $17.5 billion in low-interest loans. These funds target long-lead components for 10 new Westinghouse AP1000 reactors covering five project sites nationwide.

zacks.com2026-06-19

Mirion Technologies (MIR) Moves 5.4% Higher: Will This Strength Last?

Mirion Technologies (MIR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

gurufocus.com2026-06-10

Mirion Technologies Inc (MIR) Shares Fall 6.9% -- GF Value Says Still Overvalued

On June 10, 2026, Mirion Technologies Inc (MIR) shares fell 6.9% today, bringing the current price to $15.82. Over the past month, shares have decreased by 16.7

zacks.com2026-06-03

Watch 3 AI-Powered Nuclear Energy OEMs Amid Double-Digit Price Upside

MIR, BWXT and GEV offer notable upside based on AI data center power demand boosting nuclear OEMs.

gurufocus.com2026-05-27

A Look at Mirion Technologies Inc (MIR) After 5.8% Decline -- GF Value $13.12 vs Price $16.96

On May 27, 2026, Mirion Technologies Inc (MIR) shares fell 5.8% today, bringing the current price to $16.96. Over the past year, the stock has experienced a dec

fool.com2026-05-27

Insider Trims Stake in Mirion Technologies by $165K: What Investors Should Know

This radiation safety specialist operates across healthcare and industry; a key insider recently reduced their direct holdings.

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-06-30

"MIR reported Q2’26 revenue of $266.8M (+3.6% QoQ; +19.8% YoY) and net income of $7.7M, swinging from a net loss of -$3.4M in Q1’26 and up from $8.3M in Q2’25 (-7.2% YoY). EPS was $0.03, compared with -$0.0139 in Q1’26 and +$0.0369 in Q2’25. Profitability improved sequentially: gross margin rose to ~49.9% from ~46.2% in Q1’26, and operating income increased to $17.9M (operating margin ~6.7% vs ~1.4% in Q1). However, over the last four quarters gross margin has been volatile (mid-40%s to ~49.9%), and net margin compressed vs Q2’25 (2.9% vs 3.7%). Operating cash flow was $58.5M in Q2’26 and free cash flow was $48.1M, both well above Q1’26 (FCF $9.4M), supporting the profit rebound. Balance sheet strength increased: cash rose to $418.7M and total assets were $3.52B. Total shareholder returns appear favorable given a strong 1-year price gain (+42.5%) despite no dividends (dividend yield 0) and ongoing modest buybacks (-$25.8M in Q2)."

Revenue Growth

Good

Revenue grew +3.6% QoQ ($266.8M vs $257.6M) and +19.8% YoY ($266.8M vs $222.9M), indicating solid top-line momentum heading into Q2.

Profitability

Positive

Net income rebounded QoQ to $7.7M (from -$3.4M) and operating margin improved to ~6.7% (from ~1.4%). YoY, net income declined -7.2% and net margin eased to ~2.9% (from ~3.7%).

Cash Flow Quality

Positive

Operating cash flow was $58.5M and free cash flow $48.1M, materially stronger than Q1’26 (FCF $9.4M). No dividends; buybacks occurred (-$25.8M), and cash flow coverage improved sequentially.

Leverage & Balance Sheet

Positive

Liquidity strengthened with cash rising to $418.7M and current ratio ~3.20. Leverage remains meaningful (total debt ~$789.5M; net debt ~$370.8M), but equity is sizable ($1.93B) and assets increased slightly QoQ.

Shareholder Returns

Good

Strong price momentum: +42.5% over 1 year. Dividend yield is 0; buybacks were modest in Q2 (-$25.8M). Overall total return profile is boosted mainly by capital appreciation.

Analyst Sentiment & Valuation

Neutral

Street consensus target is ~$26.75 vs price ~$19.72 (implied upside ~35%). Valuation multiples appear elevated (e.g., price/earnings in the hundreds due to volatile earnings), warranting caution.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Mirion’s Q2 shows accelerating margin performance alongside strong nuclear backlog growth, with ~$1.1B backlog up ~40% YoY and legacy backlog up 17% (installed base up ~40%). Adjusted EBITDA margins expanded 150 bps YoY (+150 bps consolidated; >200 bps ex M&A and a ~$1M tariff refund). The company maintained full-year guidance, forecasting a meaningful second-half step-up: organic growth back half 7.5%–11.2% and 2H adjusted EBITDA margins ~27%–29% (+~150 bps vs last year). Nuclear & safety revenue grew 31% with Paragon driving continued integration-driven margin expansion (~70 bps in segment). Medical faced pressure: nuclear medicine hardware demand delayed (guide reduced to mid-single-digits) and dosimetry turned negative (less hardware revenue), though RTQA software momentum and improved factory lead times underpin back-half recovery. Key risk flagged was an ~$18M China debooking; management said it is rare, non-recurring, and immaterial to FY2026.

AI IconGrowth Catalysts

  • Backlog expansion tied to nuclear power demand across operating fleet “catch-up” spending, life extensions/upgrades, and digital transformation
  • SMR momentum: $49M of SMR orders booked in Q2 (inclusive of previously discussed large opportunities), up $42M vs last year
  • Paragon integration driving nuclear & safety adjusted EBITDA margin expansion (15% revenue growth in quarter; 27% YTD)
  • Medical software strength within RTQA, including strong double-digit order growth in first half and OEM-driven demand
  • AI-enabled product development and organization-wide efficiencies (AI pillars: faster product cycles, back-office automation, AI-powered solutions like PlanAI and Daily QA4 Pro)

Business Development

  • Constellation and Walmart announced a new nuclear power agreement (Walmart retailer + nuclear facility demand)
  • NRC licensing process update proposal to streamline approvals (regulatory catalyst supporting North America nuclear momentum)
  • DOE $17.5B loan program to support new reactor builds
  • DOE reactor pilot program achieved criticality across four advanced reactor designs by July 4 (Mirion: Paragon and Certrec “in the mix” on each design)
  • U.S. deal with Saudi Arabia to supply new reactors and nuclear technology (incremental nuclear demand avenue)
  • July large order awards: >$50M in first two weeks (including a large European installed base order and a U.S. DOE order)
  • Large opportunity wins in Q2: previously disclosed large SMR order at Paragon; second part of another SMR order; portion of radioactive waste handling order in defense/diversified

AI IconFinancial Highlights

  • Q2 revenue $266.8M (+19.7% YoY; +20% stated; organic +1% vs April expectations)
  • Adjusted EBITDA $65.3M; margin expansion +150 bps YoY (driven by favorable mix and pricing); ex M&A and one-time tariff refund, expansion would be >200 bps
  • Paragon/nuclear & safety: Q2 revenue $186M (+31% YoY), organic +2.3%; adjusted EBITDA margins expanded ~70 bps
  • Medical: Q2 revenue $81M (-1% YoY); organic revenue -1% (delayed hardware demand in nuclear medicine; difficult dosimetry hardware comp)
  • Adjusted EPS $0.12 per share in Q2 (2026 adjusted EPS now includes stock-based compensation; prior-year comparable would have been $0.09 using similar method)
  • Backlog: Q2 total backlog >$1.1B (+~40% vs year ago); legacy backlog (excluding Paragon/Certrec additions) +17%; legacy installed base +~40%
  • Revenue coverage: ~81% of expected full-year revenue accounted for by first half actual results + backlog expected to convert in second half (comparable coverage vs prior years)
  • Tariff/tax items: received ~$1M in tariff refunds to date; one-time tariff refund headwind/benefit noted as affecting margin expansion

AI IconCapital Funding

  • Share repurchase: used ~$25M of the $100M program in Q2 to buy back ~1.4M shares
  • Total buybacks for the year: ~ $40M; remaining authorization: ~$40M
  • Adjusted free cash flow: $49M in Q2; $60M through first half 2026

AI IconStrategy & Ops

  • Integration/synergy focus post-Paragon/Certrec: management expects continued adjusted EBITDA margin expansion as integration areas are captured
  • Medical factory/operations improvements: ERP implementation + factory consolidation lowered lead times, increasing ability to book/ship in fewer quarters
  • Nuclear order pipeline management: large opportunity wins tracked via $10M+ opportunities with >50% probability-of-win screening; management emphasizes timing risk as the primary swing factor
  • Backlog risk management: continuous scrutiny; debooking described as rare/unusual events tied to project progress/geopolitical/trading dynamics

AI IconMarket Outlook

  • Full-year 2026 guidance maintained (revenue and segment guidance unchanged from April)
  • Organic revenue growth guidance for full year: Q1 +2%; expected back half to step up to 7.5%–11.2% organic growth
  • Adjusted EBITDA margins: 2H expected ~27%–29% (up ~150 bps vs last year); 1H margins 22.8% (-23 bps YoY)
  • Second-half adjusted free cash flow forecast: $95M–$115M; trending toward the high end of the range
  • Q3 guidance: consolidated organic revenue growth high single-digits; nuclear & safety mid-single-digits; medical high single-digit
  • Q3 guidance on margins: consolidated adjusted EBITDA margins expand vs last year; nuclear & safety margins expected to contract; medical margins expected to expand

AI IconRisks & Headwinds

  • China debooking/cancellation: an ~$18M Chinese new build order debooked in July (booked since 2019) due to stalled project progress amid geopolitical tensions; management states no impact to FY2026 guidance and immaterial long-range guide impact
  • Nuclear medicine delayed hardware demand leading to lowered full-year nuclear medicine organic guide to mid-single-digits (from prior double-digit)
  • Dosimetry: full-year organic revenue guide cut to negative (from prior flat), driven by less hardware revenue and lapping tough 2025 hardware comp
  • Timing risk across large opportunity pipeline (projects can move right depending on sector/project nature)
  • Medical comps/tariff-related pull-forward: Q1 organic held back by tariff-related medical comps and a difficult Q1 2025 nuclear power comp

Q&A: Analyst Interest

  • Pipeline win-rate and “right to win” framing: Management said opportunities are screened at $10M+ with >50% probability of winning, and they expect to win those transacting. They noted the only major risk is timing (projects can move right), while the set is replenishing.
  • China debooking rationale and backlog quality: Management described debooks as exceedingly rare, tied to unusual contract circumstances. For China, they said the contract lacked an exit provision, but project progress was minimal and trading dynamics between the U.S. and China changed. They emphasized high backlog quality and no broader elevated risk.
  • Nuclear medicine reduced hardware volume and back-half confidence: Management said there was a pause in the first half while awaiting more drug pipeline momentum, while nuclear medicine software orders grew strongly. They linked pickup confidence to improved factory performance after ERP implementation and factory consolidation, driving much lower lead times and better booking/shipping agility.

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the MIR Q2 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for MIR.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (MIR)

© 2026 Stock Market Info — Mirion Technologies, Inc. (MIR) Financial Profile